Genmab — December 2012
-
mere head to head ritux agtigt forsøg
-
ofa beater ritux
-
24% vs 12%
-
i cr
-
Konklusion
-
Ofa er superior over RTX i preklinikken
-
O-Chop 100% ORR
-
selv med 67% flipi score
-
så OFA kan i flere indikationer
-
very encouraging data
-
fra både gsk og så også de individuelle
-
så er der Thomas Bowers
-
fra Daaanske
-
de har advanced plans med monoterapi med daratumumab
-
og de vil komme med mere news i 2013
-
så er der begejstring fra Harvard
-
accelerated approval er very real
-
afhængig af data indenfor de 6 måneder
-
det er det første antistof der viser monoterapi effekt
-
wouw Paul, you just added value
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind